A detailed history of Abg Innovation Capital Partners Iii Gp LTD transactions in Castle Biosciences Inc stock. As of the latest transaction made, Abg Innovation Capital Partners Iii Gp LTD holds 36,747 shares of CSTL stock, worth $1.22 Million. This represents 95.46% of its overall portfolio holdings.

Number of Shares
36,747
Previous 33,626 9.28%
Holding current value
$1.22 Million
Previous $744,000 7.39%
% of portfolio
95.46%
Previous 92.31%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.84 - $24.94 $58,799 - $77,837
3,121 Added 9.28%
36,747 $799,000
Q1 2024

May 15, 2024

SELL
$18.06 - $25.3 $56,365 - $78,961
-3,121 Reduced 8.49%
33,626 $744,000
Q4 2023

Feb 14, 2024

BUY
$12.19 - $22.43 $38,044 - $70,004
3,121 Added 9.28%
36,747 $793,000
Q2 2022

Aug 15, 2022

BUY
$16.0 - $45.99 $538,016 - $1.55 Million
33,626 New
33,626 $738,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $872M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Abg Innovation Capital Partners Iii Gp LTD Portfolio

Follow Abg Innovation Capital Partners Iii Gp LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abg Innovation Capital Partners Iii Gp LTD, based on Form 13F filings with the SEC.

News

Stay updated on Abg Innovation Capital Partners Iii Gp LTD with notifications on news.